Healthcare >> Analyst Interviews >> June 29, 1998
TWST: Melissa, why should women's health care be regarded as a separate MELISSA WILMOTH is a Senior Analyst, Medical Technology and Supplies at
Salomon Smith Barney. Ms. Wilmoth joined Smith Barney's Research
Division in 1996 and covers small capitalization medical technology and
supply stocks. She is actively involved in developing M&A and strategic
investment ideas for many of Smith Barney's medtech investment banking
clients. She is frequently cited in the media for her expertise in
women's health. Prior to joining Smith Barney, Ms. Wilmoth was a
managing director at Cameron Associates and most of her professional
experience has been in the health care industry. Upon receiving her B.A.
at the University of Arizona, Ms. Wilmoth began her career in sales at
American Hospital Supply in Boston. Following completion of her M.B.A.
at the University of Southern California, she was an angioplasty balloon
product manager at the USCI division of C.R. Bard where she developed a
novel angioplasty balloon catheter. Additionally, Ms. Wilmoth also
evaluated emerging technologies for commercial viability including
stents, lasers and atherectomy devices. Profile
ANNE MALONE joined Salomon Smith Barney in June, 1996 as a Vice
President and Senior Analyst, covering the medical technology industry.
Prior to joining Salomon Smith Barney, Ms. Malone worked at Bear,
Stearns & Co. for seven years, spending the last three and a half years
following medical technology stocks. She is a Chartered Financial
Analyst and a member of the New York Society of Analysts. Ms. Malone
received a B.A. in Finance with a minor in economics from St. Leo
College in June, 1988. Ms. Malone has spent more than seven years in the
investment business. Profile
segment of health care?
Ms. Wilmoth: Demographics. If you look at the burden on our health care
system, say, in the